News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Flamel Technologies (FLML) Announces Termination Of Licensing Agreement With Biovail Laboratories Inc. For Genvir And Recovery Of Rights



10/19/2005 5:12:55 PM

LYON, France--(BUSINESS WIRE)--March 3, 2005--Flamel Technologies S.A. ("Flamel") (Nasdaq:FLML) announced today that it has terminated the License Agreement with Biovail Laboratories Inc. ("Biovail") for Flamel's long-acting acyclovir formulation, Genvir(R). The License Agreement, which was signed in February 2003, granted a license to Biovail in the U.S. and Canada, subject to initiation by Biovail of certain clinical trials in the United States. The License Agreement provided for termination by Flamel in the event the clinical trials were not initiated by a date set out in the License Agreement. Gerard Soula, PhD., founder, president and chief executive officer of Flamel, said, "Despite having granted additional time to Biovail, we regret that so much time has passed without initiation of U.S. clinical trials. We believe that now is the time to work actively to find another partner to conduct these trials and to handle registration and marketing of Genvir(R)".

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES